Please Wait...

CXCL13 // C-X-C motif chemokine 13

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

CXCL13 (also known as BCA-1 or BLC) is a 10.46kDa protein of 88 residues. Its receptor, CXCR5, is expressed by TFH cells in the follicle (TFH outside the follicle do not express CXCR5). For example, CXCR5 is expressed in the TFH cells which help B cells to differentiate in long lived plasma cells (Tangye et al., 2013).

Blocking the internalization of CXCR5 in mouse, with an anti-CXCL13 antibody, results in impairment of B cell homing in secondary lymphoid organ. It also attenuates symptoms in a model of autoimmune encephalomyelitis (Klimatcheva et al., 2015).

Elevated levels of CXCL13 in serum are detected in several inflammatory diseases such as rheumatoid arthritis, primary Sjörgren’s syndrome and for neuroinflammation (Alvarez et al., 2013; Jones et al., 2014; Kowarik et al., 2012; Nocturne et al., 2015).


CXCL13 assay is a solid phase enzyme linked immunoassay which has been validated in the laboratory for measurement in human serum.


Alvarez, E., Piccio, L., Mikesell, R.J., Klawiter, E.C., Parks, B.J., Naismith, R.T., and Cross, A.H. (2013). CXCL13 is a Biomarker of Inflammation in Multiple Sclerosis, Neuromyelitis Optica, and Other Neurological Conditions. Mult. Scler. Houndmills Basingstoke Engl. 19, 1204–1208.

Jones, J.D., Hamilton, B.J., Challener, G.J., de Brum-Fernandes, A.J., Cossette, P., Liang, P., Masetto, A., Ménard, H.A., Carrier, N., Boyle, D.L., et al. (2014). Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels. Arthritis Res. Ther. 16, R103.

Klimatcheva, E., Pandina, T., Reilly, C., Torno, S., Bussler, H., Scrivens, M., Jonason, A., Mallow, C., Doherty, M., Paris, M., et al. (2015). CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol. 16, 6.

Kowarik, M.C., Cepok, S., Sellner, J., Grummel, V., Weber, M.S., Korn, T., Berthele, A., and Hemmer, B. (2012). CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J. Neuroinflammation 9, 93.

Nocturne, G., Seror, R., Fogel, O., Belkhir, R., Boudaoud, S., Saraux, A., Larroche, C., Le Guern, V., Gottenberg, J.E., and Mariette, X. (2015). CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sjögren Syndrome: CXCL13, CCL11 and disease activity in pSS. Arthritis Rheumatol. n/a – n/a.

Tangye, S.G., Ma, C.S., Brink, R., and Deenick, E.K. (2013). The good, the bad and the ugly — TFH cells in human health and disease. Nat. Rev. Immunol. 13, 412–426.


Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @bioclinica: @CardiacSafety Consortium needs your feedback! Help make the upcoming think tank "Evaluation of #MobileTechnologies in #CV…
bioclinica (5 minutes ago)
@CardiacSafety Consortium needs your feedback! Help make the upcoming think tank "Evaluation of…
bioclinica (10 minutes ago)
RT @CDISC: Special thanks to CDISC Member @bioclinica for hosting CDISC Public Training in Audubon, PA 2-6 Apr 2018. Register today. https:…
bioclinica (26 minutes ago)
Bioclinica Delivers Individual Case Safety Report (ICSR) Processing w Quality & Consistency While Crossing One Mil…
bioclinica (Yesterday)
Who made the BioSpace list of 11 most innovative life sciences companies in the world? Ck it out here via @biospace…
bioclinica (Yesterday)
BREAKING: With a passion for Drug Safety, we’re delighted to share @bioclinica #pharmacovigilance crossed 1M ICSR c…
bioclinica (2 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen